Duke University
Durham, United States
Dr. John Strickler is an Associate Professor at Duke University, where he is the Associate Director of Clinical Research – GI Oncology and Co-Leader of the Molecular Tumor Board. He received his B.A. from the University of North Carolina at Chapel Hill and his M.D. from the University of Chicago - Pritzker School of Medicine. He completed his residency in Internal Medicine at the University of Washington and fellowship in Hematology and Medical Oncology at Duke University. Dr. Strickler’s clinic specializes on the treatment of gastrointestinal malignancies, with a particular emphasis on esophageal, gastric, pancreatic and colorectal cancers. His research focuses on precision cancer medicine: identification of genomic biomarkers that predict sensitivity or resistance to targeted therapies and immunotherapy. He has a particular interest in non-invasive “liquid biopsies” to deliver on the promise of precision cancer medicine. He has designed and executed clinical trials that test novel therapies and innovative therapeutic strategies. He was Principal Investigator on an investigator sponsored trial that led to the first FDA-approved therapy for HER2+ metastatic colorectal cancer. Nationally, he is co-Chair of the GI Steering Committee for the Academic and Community Cancer Research United (ACCRU) clinical trial consortium and he is a member of the American Society of Clinical Oncology (ASCO) Treatment Guidelines Committee for Advanced Colon Cancer.
Friday, June 30, 2023
09:30 – 09:50 CEST